Lepu Biopharma (HKG:2157) expects a profit of at least 24 million yuan in the first half of 2025, compared with a loss of 197 million yuan a year prior, a Wednesday Hong Kong bourse filing said.
This marks the first time the biopharmaceutical company is anticipated to record a profit, according to the filing.
The firm attributed the forecast to a significantly higher revenue, including income from a licensing collaboration with ArriVent BioPharma and sales revenue from the pucotenlimab injection.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.